most common type of values clarification method. Most methods did not allow users to add their own concerns. Few methods explicitly presented tradeoffs inherent in the decision, supported an iterative process of values exploration, or showed how different options aligned with users' values. Limitations. Study selection criteria and choice of elements for the taxonomy may have excluded values clarification methods or design features. Conclusions. Explicit values clarification methods have diverse designs but can be systematically cataloged within the structure of a taxonomy. Developers of values clarification methods should carefully consider each of the design features in this taxonomy and publish adequate descriptions of their designs. More research is needed to study the effects of different design features. Key words: values clarification; values clarification exercise; values clarification method; values; clarify; decision making; decision aids; shared decision making; design; preferences. (Med Decis Making 2016; 36:453-471) I ndividual values are a critical ingredient in highquality decision making and, indeed, in high-quality care. [1] [2] [3] [4] What is important to one person may not be the same as what is important to others. Thus, a common definition of an informed decision begins with 2 foundational elements: such a choice must be based on relevant knowledge, and it must be congruent with the individual's values. 5, 6 Considerable work has been done on the first element to determine how best to ensure that people have relevant knowledge before making health decisions. [7] [8] [9] [10] Although such evidence is not always consistently implemented within decision support tools, researchers and practitioners can look to best practices for guidance on how to present health information. 11, 12 There is considerably less consensus on the second element. Although there is widespread agreement that supporting the process of values clarification is a key step in effective decision making, 4, [12] [13] [14] to the point that inclusion of such a component has been used as a metric of quality of decision support tools, 15 there are no established best practices for values clarification. 16, 17 This may be attributable at least partly to the fact that activities described as values clarification are extremely varied. They include tasks such as identifying pros and cons of an option, 13 rating 18 or ranking 19 the importance of these specific risks or benefits, indicating whether each piece of information pushes one toward or away from a given choice, 20 viewing a ''soap opera'' whose characters are faced with a medical decision and choosing the character with whom one most identifies, 21 or having an open discussion about attributes of interest. 22 All of these activities are designed to achieve the goal of helping people clarify their values relevant to a given decision. However, they have vastly different features, which makes it difficult to compare and contrast different designs, draw conclusions about their comparative effectiveness, and thus make decisions about how we can best help people clarify their values relevant to a health decision.
To begin to build an evidence base concerning values clarification, we undertook a systematic review of explicit values clarification methods. The aim of this article is to catalog the diverse methods that have been described in the literature. The cataloguing scheme-or taxonomy-will also serve to provide structure for the development and reporting of values clarification methods, as well as for studying the effects of different design features.
Values, Values Clarification, and Preferences
The terms values, values clarification, and preferences are used in a number of ways in the literature.
Values may refer to broad principles such as valuing family or to more specific concepts such as the extent to which decision attributes matter to an individual. In this review, the term values refers to the latter, narrower meaning, and we therefore refer to values clarification as it is commonly used in the medical decision-making literature, meaning the process of sorting out what matters to an individual relevant to a given health decision. Similarly, the term preferences refers to an individual's inclination toward or away from a given decision option. According to these definitions, values clarification methods should help people sort out what matters to them, which should, in turn, help determine preferences. We note that the related terms values elicitation and preference elicitation refer to processes by which values and preferences, respectively, are drawn out.
METHODS

Inclusion and Exclusion Criteria
Articles were included in this review if they sufficiently described the design of an explicit values clarification method intended to assist someone in making an individual-level health decision. We defined an explicit method as one in which the user of the method explicitly interacted with an interface, for example, by shading in boxes in a booklet or moving a slider in a web-based application. Articles were considered to have described a method sufficiently if screeners deemed that it would be possible to extract data for a minimum of 10 of the 12 design features in our taxonomy, either because the information was contained in the text of the article, in an appendix, or if the article included a URL freely linking to a copy of the values clarification method. An included values clarification method could be part of a decision aid but could also be an independent intervention or another type of intervention. In addition, an article could conceivably describe more than 1 values clarification method. We excluded articles that described a decision aid and mentioned that a values clarification method was included but did not describe the method in sufficient detail or used an implicit method.
Search Strategy
With assistance from 2 medical librarians to develop and deploy our search strategy, we conducted a systematic search to identify published accounts of values clarification methods. We searched MEDLINE, all EBM Reviews, CINAHL, and EMBASE for either value or values and clarif* within 5 words of each other in abstracts and titles. For CINAHL, we also used the major subject heading ''Values Clarification.'' In addition, we searched Google Scholar for values clarification exercise, the term used until recently to describe such interactive tools. 17 We also included all articles that either cited the previous version of the International Patient Decision Aid Standards (IPDAS) guidelines 12 or were included in the most recent published Cochrane review of decision aids at the time of the search. 23 Two searches were conducted: the first on 17 December 2010 and an update using the same search strings and methods on 29 January 2014. We did not use date or language restrictions. This strategy yielded a total of 2629 articles after duplicates were removed (2145 in the initial search and 484 in the update). We also searched references of included articles in which the articles referred to previous designs not included in our original set, consulted with experts to identify any articles that might have been missed, and reviewed all articles added in the update to the Cochrane systematic review of decision aids, which was in process at the time of this review. 9 These steps yielded an additional 3, 4, and 23 articles, respectively. Thus, we screened a total of 2659 articles.
Screening Process
Two authors (H.O.W. plus one of L.D.S., T.G., S.C.D.) independently screened all articles. Discrepancies were resolved by discussion until consensus was reached.
Quality Appraisal
Because we sought descriptive articles, no quality appraisal beyond our inclusion criteria was necessary.
Development of the Taxonomy
The overall structure of the taxonomy was developed collaboratively by all authors. We posed broad questions and iteratively reviewed the data to refine each data element and its categories. The broad questions posed were: 1) For what decision was this values clarification method created? 2) What theory, framework, guidelines, and previous work guided its design? 3) What were the design features of the method?
In identifying design features, we aimed to describe a taxonomy of design choices that developers of values clarification methods must makedeliberately or not-that determine how users may interact with a given values clarification method. To develop the taxonomy, we used an iterative method of constant comparison, in which we identified design features that distinguished different values clarification methods from each other, examined those features across methods, discussed the features among data extractors (H.O.W., L.D.S., T.G., A.H.P., A.F.-F., S.C.D.), consulted with other authors, revised definitions and categories, and ultimately arrived at the structure described below.
Data Extraction
One author (H.O.W.) extracted all data into evidence tables, which were subsequently reviewed in detail by 5 authors (L.D.S., T.G., A.H.P., A.F.-F., S.C.D.), each of whom examined specific columns, identified any data of concern, and resolved any issues together with H.O.W. Items for which further information was deemed necessary were referred for consultation with authors of the original articles.
Data Synthesis
Summary statistics were calculated in Microsoft Excel. 24
Analysis
We explored whether it would be possible to simplify the taxonomy of design features by examining pairwise comparisons between design features and by applying latent class analysis. Latent class analysis is similar to factor analysis but is better suited to categorical data. Analyses were performed in R, version 3.0.2, 25 using the poLCA package for latent class analysis. 26
RESULTS
Overview of Included Studies
This review includes 110 articles describing 98 explicit values clarification methods. See Figure 1 for details of the identification, screening, and VALUES CLARIFICATION DESIGN FEATURES: SYSTEMATIC REVIEW Abhyankar and others 27 1 Choice between standard adjuvant chemotherapy for early-stage breast cancer and clinical trial testing new chemotherapy Abreu and others 28 1 Choice between 2 different treatments (oral and intravenous) for systemic lupus erythematosus Achaval and others 29 1 Whether or not to have total knee arthroplasty to treat knee osteoarthritis in cases of pain and disability unresponsive to medical treatment Akl and others 30 1 Whether or not to take inhaled steroids to treat chronic obstructive pulmonary disease Alfaleh and others 31 1 Whether to use prophylactic indomethacin therapy or wait and treat symptomatic patent ductus arteriosus in extremely-lowbirth-weight infants Allen and others 32 1 Whether or not to have PSA testing to screen for prostate cancer Bastian and others 33 1 Whether or not to take hormone replacement therapy Bekker and others 34 1 Whether or not to have a diagnostic test for Down syndrome after receiving a positive screen in maternal serum screening Berger and others 35 1
What lifestyle changes to implement in the context of a cardiac condition Brenner and others 36 2 Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (4 unlabeled screening tests designed to simulate fecal occult blood testing, sigmoidoscopy, colonoscopy, or a radiological test such as computed tomography colonography) Breslin and others 37, 38 1 Choice between treatments for type 2 diabetes Brundage and others 39, 40 1 Choice between combined modality treatment or radiation alone for non-small-cell lung cancer Chiew and others 41 1 Whether or not to have chemotherapy in addition to supportive care in the context of advanced breast cancer Clancy and others 42 1 Choice between being immunized for hepatitis B, screened for antibodies and immunized if negative, or not immunized unless exposed Costanza and others 43 1 Whether or not to have PSA testing to screen for prostate cancer Culver and others 44 1 Whether to have a risk-reducing mastectomy, risk-reducing salpingo-oopherectomy before age 50, or take tamoxifen for 5 y Dolan and Frisina 45 1 Choice between 5 active options (annual FOBT, flexible sigmoidoscopy every 5 y, annual FOBT + flexible sigmoidoscopy every 5 y, barium enema every 5 y, colonoscopy every 10 y) and a wait-and-see approach to colorectal screening Dolan and others 46 1 Which medication to use for treatment of knee osteoarthritis pain Dorfman and others 47 2 Whether or not to have PSA testing to screen for prostate cancer Drake and others 48 1 Whether or not to have prenatal screening for major fetal chromosome abnormalities, and if yes, choice between different tests or combinations of tests (maternal serum screening, chorionic villus sampling, amniocentesis) Durand and others 49 2 Whether or not to have amniocentesis after having been identified as high risk via less invasive screening tests Emmett and others 50 1 Choice between a repeat cesarean or vaginal birth after cesarean (VBAC) Evans and others 51 1 Whether or not to have PSA testing to screen for prostate cancer Feldman-Stewart and others 52 1 Choice between watchful waiting, radiation, and surgery for treatment of early-stage prostate cancer 
Number of Values Clarification Methods Described in Article(s) Decision
Feldman-Stewart and others 20,53 2 Choice between 4 main options for early-stage prostate cancer (watchful waiting, surgery, external beam radiation, and brachytherapy) Fraenkel and others 54 1 Choice between treatments for knee pain (capsaicin, acetaminophen, anti-inflammatory drugs, intra-articular injections, exercise, exercise + medications) Fraenkel and others 55, 56 1 Whether or not to take warfarin, aspirin, or neither to prevent stroke Frosch and others 57, 58 1
Whether or not to be screened for prostate cancer Garvelink and others 59 1 Whether or not to use fertility preservation methods and, if so, which (cryopreservation of embryos, cryopreservation of ovarian tissue and cryopreservation of oocytes) Gattellari and Ward 60 1 Whether or not to have PSA testing to screen for prostate cancer Goodlin and others 61 1 A variety of decisions relevant to heart failure Green and Levi 62 1 Preferences for end-of-life care Hawley and others 63 1 Choice between methods for colorectal screening Hunter and others 22 1 Whether or not to have prenatal screening for major fetal chromosome abnormalities and, if yes, choice between different tests or combinations of tests (maternal serum screening, chorionic villus sampling, amniocentesis) Jackson and others 64, 65 1 Whether or not to immunize one's child with MMR vaccine Jibaja-Weiss and others [66] [67] [68] 1 Choices between treatments for early breast cancer Karel and others 69 1
Preferences (values and goals) for advance care planning in case of decisional incapacity Karel and others 70 3 Preferences for advance care planning in case of decisional incapacity Kasper and others 71 1 Whether or not to have immunotherapy for multiple sclerosis, and if yes, what kind of therapy to have Kennedy and others 72 1 Choice between treatment options for menorrhagia (advice and reassurance, addressing possible iatrogenic causes, drug therapy, or surgery such as hysterectomy or endometrial destruction) Labrecque and others 73 1 Whether or not to have a vasectomy Lalonde and others 74, 75 1 Whether or not to start lifestyle changes and antihypertensive or lipid-lowering pharmacotherapy Legare and others 76 1 Whether or not to use natural health products for menopausal symptoms (and, if so, which one[s]) Leighl and others 77 1 Choice between supportive care only, supportive care plus usual care chemotherapy, or supportive care plus clinical trial participation in the context of metastatic non-small-cell lung cancer Lepore and others 78 1 Whether or not to be screened for prostate cancer Lerman and others 79 1 Whether or not to have genetic testing for BRCA1 Lewis and others 80 1 Whether or not to be screened for colorectal cancer Llewellyn-Thomas and others 81, 82 1 Choice between watchful waiting, alpha blocker, and transurethral resection of the prostate in the context of benign prostatic hyperplasia Matheis-Kraft and Roberto 83 1 Preferences for care in case of decisional incapacity Mathieu and others 84 1 Whether or not to continue or stop mammography screening at age 70
Mathieu and others 85 1 Whether to begin mammography screening at age 40-49 or wait until age 50 Montgomery and others 86 1 Whether or not to start drug therapy for hypertension Moumjid and others 87 1 Choice between treatments and combinations of treatments for breast cancer (mastectomy or lumpectomy, axillary dissection or sentinel node biopsy, adjuvant chemotherapy or not) Myers 88 3
Whether or not to participate in a prostate cancer prevention clinical trial Nassar and others 89, 90 1 Whether or not to have an external cephalic version for a breechpresenting baby O'Connor and others 13,91- 93 1 Whether or not to take hormone replacement therapy after menopause van Peperstraten and others 18 1 Choice of how many embryos to transfer during in vitro fertilization (either 1 or 2) Peshkin and others 94 1 Whether or not to disclose BRCA1/2 genetic testing results to one's minor children and, if so, how Pieterse and others 95 1 Whether or not to have preoperative radiotherapy (prior to surgery) for treating rectal cancer Pignone and others 96 2 Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (4 unlabeled screening tests designed to simulate fecal occult blood testing, sigmoidoscopy, colonoscopy, or a radiological test such as computed tomography colonography) Pignone and others 97 2 Whether or not to be screened for prostate cancer Protheroe and others 98 1 Whether or not to initiate active treatment for menorrhagia, choice between treatments Raats and others 99 1 Generic design, not specific to a given decision Rimer and others 100, 101 1 Whether or not to have mammography to screen for breast cancer van Roosmalen and others 102 1 Choice between intensive screening and prophylactic surgery for breasts and/or ovaries Rothert and others 103 1 Whether or not to take hormone replacement therapy Ruffin and others 104 1 Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (FOBT, flexible sigmoidoscopy, colonoscopy, or double contrast barium enema) Sawka and others 105, 106 1 Choice between lumpectomy with radiation and mastectomy for early breast cancer Schapira and others 107 1 Whether or not to take hormone replacement therapy Schonberg and others 108 1 Whether or not to have mammography to screen for breast cancer Schwalm and others 109 1 Whether to use femoral or radial access for coronary angiography Segal and Shahar 114 1 Whether or not to have a triple screen test, amniocentesis, and second trimester ultrasound Sheridan and others 19 1 Whether or not to initiate behaviors to prevent coronary heart disease, and, if so, which behaviors Shorten and others 111, 112 1 Choice between a repeat cesarean or vaginal birth after cesarean Singer 113 1 Choice between ways to deal with an unplanned pregnancy (abortion, adoption, parenting) Smith and others 114, 115 2 Whether or not to have screening for bowel cancer via FOBT screening every 2 y Sorenson and others 116 1 Whether or not to have hemophilia A genetic carrier testing Thomson and others 117 1 Whether or not to take warfarin to prevent stroke (continued) eligibility assessment of articles; Table 1 for a list of included articles; and Table 2 for full descriptive statistics of the values clarification methods. Methods in this review addressed a wide range of decisions. Cancer was the most common clinical context (49%), followed by reproductive health (19%). Screening and treatment decisions dominated the types of decisions, representing 75% of contexts. Nearly half of methods (46%) were designed to support a decision of whether or not to accept an option, while others supported a decision between 2 or more options (24%) or a combination (28%) in which users would decide whether or not to pursue an option (for example, a screening test) and would then choose from among types of that option (for example, different screening tests). Among included methods, 45% were designed for use by both men and women, 36% only by women, and 19% only by men. The difference between these latter 2 statistics is attributable to differences in the clinical context of reproductive health, in which 17 methods addressed issues relevant to women's reproductive health and 1 addressed an issue (vasectomy) relevant to men's reproductive health.
Foundations
Using a broad, inclusive definition, only 38% of explicit values clarification methods were built on a foundation such as a theory, framework, model, or theoretically based approach applicable to values clarification. Among those that did, most (28/38, or 74%) referenced or implied theories or theoretically based approaches such as expected utility theory or conjoint analysis, which are not descriptive theories of values clarification, meaning they do not describe the details of how people engage in the process of values clarification. Few methods (21%) were based on a previous design of a values clarification method. Considering the full set of published methods, most (64%) cited no relevant guidelines. Of those that did, the IPDAS, first published in 2006, was the most frequently used overall (26%). Of the 78 methods described in articles published in 2007 or later, after these standards were published, 56% (44/78) still cited no guideline. Table  3 gives details about Foundations.
Taxonomy of Design Features
The categories within each design feature are described and illustrated with examples in Table 4 . Most categories are mutually exclusive. The distinction between mutually exclusive and non-mutually exclusive frequencies is noted for each entry in the table, and details are provided in the table. Pairwise comparisons revealed that no design feature entirely determined any of the others, and no latent factor was identified.
Type of Values Clarification Method
Prior to data extraction, we drafted a list of possible types, based on previous typology in the literature. 129 Thomson and others 118 1 Choice between different treatments for hypertension Tiller and others 119, 120 1 Choice of risk management strategies for ovarian cancer (annual transvaginal ovarian ultrasound then annual CA125 serum testing after menopause, prophylactic surgery, chemoprevention, prophylactic oophorectomy) Vandemheen and others 121, 122 1 Whether or not to be screened for prostate cancer Volk and others 21 1
Whether or not to be screened for prostate cancer Wakefield and others [124] [125] 2
Whether to not to undergo genetic testing or defer decision Wallace and others 126 1 Whether or not to immunize one's child with MMR vaccine Wong and others 127 1 Whether to have antiestrogens, radiation, both, or neither after lumpectomy Wroe and others 128 1 Whether or not to immunize one's baby with standard first childhood vaccines (diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenzae type b, and polio) 
Position in Decision Aid
For values clarification methods that were contained within a decision aid, we extracted data about where in the decision aid the method was placed, for example, before or after an information section, between information sections, or throughout the intervention. Most methods in the review (79/98, 81%) were contained in a decision aid; of these, most (66/79, 83%) came after a complete information section.
Solo Activity
Most values clarification methods (59%) were designed to be completed independently by the patient or person making the decision. Of methods designed to be completed with others, the most common other person was a research assistant (17%) followed by a health care provider (14%). A small number (2%) were designed to be completed with a spouse, caregiver, friend, or family member.
Media
We extracted the medium used for each values clarification method, specifically, whether the method was designed to be completed on paper, a computer, or verbally. We note that although the information in a decision aid might be presented via another format such as a DVD, an explicit values clarification method requires an interactive medium. Methods in the review were roughly balanced between paper (39%), computer based (38%), and verbal (23%).
Tradeoffs
The need for values clarification methods arises out of the challenges of making preference-sensitive decisions in which tradeoffs exist. Thus, an important aspect of the decision-making process involves understanding and determining how one feels about the relevant tradeoffs. Tradeoffs were represented explicitly in less than a third of methods (32%).
Visual Metaphors
We examined whether or not each values clarification method used any sort of visual metaphor as part of the design. By visual metaphor, we mean any sort of graphical element that was part of the values clarification method itself, for example, a set of weigh scales to illustrate the concept of a tradeoff. 13 This categorization does not apply to graphics within a decision aid that were not part of the values clarification method, such as an icon array displaying risks. Most values clarification methods (59%) contained no visual metaphor.
Open-or Closed-Ended
We noted whether the sets of attributes presented to users were closed-ended, open-ended, or mixed. Closed-ended means that users could not add concerns that were not already listed, whereas openended and mixed allowed people to include additional items of concern. The majority of methods (61%) were closed-ended, meaning that users could not add decision attributes that were not prespecified by the designers.
Elicitation Process
We examined what process the user of the values clarification method might go through to give responses about her or his values relevant to the decision. For example, the process might involve answering questions, completing standard gamble exercises, or directly rating the importance of each attribute of a decision. The majority of methods (58%) used direct scaling.
Response Measure
The response measure refers to the type of data obtained via the elicitation process. For example, data elicited might be a categorical choice yielding 
Values Exploration
Values clarification is often an iterative discovery process, 130, 131 and it can take time for preferences to stabilize. 4, 16 To establish how and whether values clarification methods supported such exploration, we extracted data about whether each design explicitly encouraged an iterative process of revision, implicitly allowed such a process but did not encourage it, or did not support iteration and required users to identify and express their values in a single attempt. Very few methods explicitly encouraged all users (9%) or users who expressed decision intentions that were incongruent with their stated values (2%) to explore their values in an iterative discovery process. Most methods (65%) were designed such that iterative revision was technically possible (e.g., users could go back within a website or could complete a paper worksheet in pencil) but not explicitly encouraged.
Implications
We extracted whether or not the design of each values clarification method showed users the implications of their expressed values. For example, a method that explicitly presents implications might give a recommended option or might present scores to show how well or poorly each option fits with the user's responses. Alternatively, a method may not explicitly show implications but may allow people to infer such information, for example, by roughly comparing the weights they have assigned to the pros versus the cons of a choice. Less than one-third of methods (29%) explicitly presented users with the implications of their stated values.
Decision Intentions
We extracted data about whether or not each method included a step in which the user is asked to indicate his or her decision intentions, whether a clear decision or a direction in which he or she is leaning. This did not include cases in which decision intentions were recorded as an outcome during a study; it refers specifically to cases in which the user was asked to express her or his decision intentions within the values clarification process itself. Slightly more than half of methods in total (54%) asked users about their decision intentions, either by asking for their decision (16%) or toward which decision they are leaning (38%).
DISCUSSION
This review demonstrates that a diverse array of explicit values clarification methods are used across a range of health decisions. It is unknown whether a given values clarification method might be equally effective for different decisions. In other words, are designs and design features specifically suited to particular decisions, or can their use in one context be justified by empirical results in another? Such comparisons are difficult because of structural differences between different decisions. For example, choosing between 2 options is fundamentally different from choosing between 3 options, 132 and different designs are possible for 2 versus 3 options. Further With binary User gives a binary response to each pro or con, for example, ''Does this sound like you?'' 7 (7) Viewing or listing only Involves only listing or viewing pros and cons; no explicit weighing or other response required 1 (1)
Math model based 19 (19) Decision analysis
Involves utility estimation via standard gamble or other methods and a decision analytic model; may include viewing a decision tree 11 (11) Conjoint User responds to multiple sets of attributes with varying levels, either one set at a time or choosing between sets via discrete choice analysis 7 (7) Analytical hierarchy process Involves decomposing decision into its attributes and weighing attributes against each other 1 (1)
Rating
Involves rating attributes or outcomes, e.g., using importance ranking scales (however, does not involve explicit identification of each attribute as a pro or con; in such a case, type is ''pros and cons with weighting'')
(18)
Prioritization Involves ranking a full list of concerns and/or selecting the top n concerns 16 (16) List of concerns 13 (13) List and discuss Involves discussing concerns from one's own list or from a preidentified list of concerns, possibly using a semistructured interview format 6 (6)
List only Involves listing one's concerns or going through a preidentified list of concerns without discussing them 4 (4)
Discuss only
Involves a discussion that takes place without a predefined list or list developed by the individual
(3)
Threshold d 9 (9) Attributes
Involves considering tradeoffs according to individual attributes, e.g., comparing medications to treat type 2 diabetes according to their impacts on blood sugar, weight, and required frequency of testing 37
(4)
Probability Involves selecting between 2 or more different probabilities 2 (2) Time Involves selecting between 2 or more different lengths of time in given health states
(2)
Outcomes or processes Involves considering tradeoffs according to individual outcomes or processes, e.g., choosing between statements, ''It is alright if my family or doctor makes medical decisions for me,'' and ''If I am able, I want to make medical decisions for myself'' 70
(1)
Social matching User observes different characters' decisions and/or decision-making processes and identifies 1 or more characters with whom she or he identifies
(2)
Other Any other type not described in above list 1 (1) Position in decision aid (DA)
After information Values clarification method placed after information section about the decision 66 (67)
Before information
Values clarification method placed before information section about the decision 2 (2)
Between information sections
Values clarification method placed between different information sections about the decision User ranks items, e.g., from most to least important; this can include completely ranking a list of issues or simply selecting the top 3 issues from a larger set 19 (19) Discrete choice User chooses between 2 or more sets of options. For example, users may be asked whether they would prefer a treatment that requires injections, has minor side effects, and a moderate out-of-pocket cost or a treatment taken by pill, with moderate side effects and a low out-ofpocket cost. Or, they may be asked to choose between 2 cards, one representing a reason to have a screening test and the other describing a related reason not to take it and are then asked to choose which is more important to them.
(12)
Answer questions
User answers open-ended questions verbally or in other ways 11 (11) Standard gamble or similar User completes a standard gamble or other similar technique that involves iterating values to find a point of indifference 7 (7) Personal relevance Users respond on the basis of personal relevance, identifying issues that apply to them or statements that ''feel like me'' 6 (6)
List items
Users are asked to make a list of items that are relevant to the decision and matter to them 4 (4)
Choose character User chooses a character from a story-based exposition with whom she or he identifies research is needed regarding how best to support values clarification across different decisions. Despite our use of an inclusive and generous description of theory, framework, model, or theoretically based approach, we found that few methods built on such a foundation. The overall low use of theories, frameworks, or models may be problematic, as such foundations can help structure hypotheses that might ultimately allow researchers to understand why and how a given values clarification method does or does not work. Similarly, few explicit values clarification methods were specifically based on previous designs. This may be a reflection of the lack of designs that have been demonstrated to be effective or simply that the field is relatively new. Further research is needed into optimal designs of explicit values clarification methods to identify and advance the use of effective design features.
The 12 design features within the taxonomy describe the heterogeneity of values clarification methods. These design features are sufficiently independent that each one should be considered when designing values clarification methods, and they should be included in reports. User is asked which way she or he is leaning; this includes methods that ask for a decision but allow some ambiguity by having an option to indicate ''unsure'' or ''uncertain'' 37 (38) Yes (decision) User is asked for her or his decision, with no option for uncertainty 16 (16) Unclear Presence or absence of this step is not clear from published description 1 (1) a. Categories are mutually exclusive unless indicated otherwise. b. Not mutually exclusive: 11 methods classified as 2 types, 3 methods classified as 3 types, and 2 combine 2 subtypes under pros and cons. c. Indentations represent subcategories contained within the category. d. These types may have similar user experiences as decision analysis and conjoint analysis, particularly discrete choice analysis. However, types classified under ''Threshold'' do not involve calculating utilities in any way, nor do they involve decision analytic modeling. e. Not mutually exclusive: 1 method used proportions and time visual metaphors together. f. Not mutually exclusive.
Limitations
While we endeavored to capture all published accounts of explicit values clarification methods, it is possible that some were missed. Similarly, for reasons of scope, we did not search gray literature, nor did we contact authors to request copies of values clarification methods that were insufficiently described in the literature. Second, although our data extraction process was such that each element was examined by at least 2 authors and we contacted authors in cases in which a description was unclear, it is possible that we misunderstood some descriptions. Finally, although we developed our taxonomy using rigorous methods, our choices of design features in the taxonomy were based on the authors' judgment and may not represent the entirety of important design features.
CONCLUSIONS
This systematic review formally demonstrates that there is a diverse array of explicit values clarification methods in use, most with neither theoretical nor empirical basis for their design. Given the growing social, legislative, and policy imperatives to help people make health-related decisions that reflect what is important to them, more research is needed into optimal designs of values clarification methods.
To build an evidence base and help move this emerging field forward, we encourage developers of values clarification methods to design with awareness of relevant theory 14 and previous designs, publish adequate descriptions of the design of their values clarification method using the taxonomy described in this review, and provide clear rationales for their design choices. There is a need for empirical evidence about the different choices for design features in this taxonomy. We advocate for more research to isolate the effects of different design features in order to better equip researchers and practitioners in medical decision making to help people clarify their values and make their best possible health decisions. 
